Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAJIC: Acalabrutinib + Venetoclax vs Venetoclax + Obinutuzumab in Untreated CLL/SLL
NCT05057494Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Primary completion
- Jul 2027
- Countries
- 7
01
Overview
A Phase 3 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by AstraZeneca. Started Sep 2022; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05057494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057494.